54 related articles for article (PubMed ID: 8610466)
1. Inhibition of HIV-1 in cell culture by synthetic humate analogues derived from hydroquinone: mechanism of inhibition.
Schneider J; Weis R; Männer C; Kary B; Werner A; Seubert BJ; Riede UN
Virology; 1996 Apr; 218(2):389-95. PubMed ID: 8610466
[TBL] [Abstract][Full Text] [Related]
2. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids.
Delézay O; Hammache D; Fantini J; Yahi N
Biochemistry; 1996 Dec; 35(49):15663-71. PubMed ID: 8961929
[TBL] [Abstract][Full Text] [Related]
3. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of a hydrophobic tripeptide on human immunodeficiency virus type 1 (HIV-1)-induced syncytium formation and viral infectivity.
Konopka K; Pretzer E; Düzgünes N
Biochem Biophys Res Commun; 1995 Mar; 208(1):75-81. PubMed ID: 7887968
[TBL] [Abstract][Full Text] [Related]
5. Role of the V2, V3, and CD4-binding domains of GP120 in curdlan sulfate neutralization sensitivity of HIV-1 during infection of T lymphocytes.
Jagodzinski PP; Wustner J; Kmieciak D; Wasik TJ; Fertala A; Sieron AL; Takahashi M; Tsuji T; Mimura T; Fung MS; Gorny MK; Kloczewiak M; Kaneko Y; Kozbor D
Virology; 1996 Dec; 226(2):217-27. PubMed ID: 8955041
[TBL] [Abstract][Full Text] [Related]
6. A monoclonal antibody to the gp120-CD4 complex has differential effect on HIV-induced syncytium formation and viral infectivity.
Konopka K; Pretzer E; Celada F; Düzgüneş N
J Gen Virol; 1995 Mar; 76 ( Pt 3)():669-79. PubMed ID: 7897355
[TBL] [Abstract][Full Text] [Related]
7. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
Verrier F; Borman AM; Brand D; Girard M
AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469
[TBL] [Abstract][Full Text] [Related]
8. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41.
Allaway GP; Ryder AM; Beaudry GA; Maddon PJ
AIDS Res Hum Retroviruses; 1993 Jul; 9(7):581-7. PubMed ID: 8369162
[TBL] [Abstract][Full Text] [Related]
9. An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step.
Barbouche R; Decroly E; Kieny MP; Fenouillet E
Virology; 2000 Jul; 273(1):169-77. PubMed ID: 10891419
[TBL] [Abstract][Full Text] [Related]
10. Molecular function of the CD4 D1 domain in coreceptor-mediated entry by HIV type 1.
Esser U; Speck RF; Deen KC; Atchison RE; Sweet R; Goldsmith MA
AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1845-54. PubMed ID: 11118070
[TBL] [Abstract][Full Text] [Related]
11. Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320).
Buckheit RW; Roberson JL; Lackman-Smith C; Wyatt JR; Vickers TA; Ecker DJ
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1497-506. PubMed ID: 7888204
[TBL] [Abstract][Full Text] [Related]
12. The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion?
Clements GJ; Price-Jones MJ; Stephens PE; Sutton C; Schulz TF; Clapham PR; McKeating JA; McClure MO; Thomson S; Marsh M
AIDS Res Hum Retroviruses; 1991 Jan; 7(1):3-16. PubMed ID: 2015114
[TBL] [Abstract][Full Text] [Related]
13. Interaction of an anti-HIV peptide, T22, with gp120 and CD4.
Tamamura H; Otaka A; Murakami T; Ishihara T; Ibuka T; Waki M; Matsumoto A; Yamamoto N; Fujii N
Biochem Biophys Res Commun; 1996 Feb; 219(2):555-9. PubMed ID: 8605026
[TBL] [Abstract][Full Text] [Related]
14. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity.
Jansen RW; Schols D; Pauwels R; De Clercq E; Meijer DK
Mol Pharmacol; 1993 Nov; 44(5):1003-7. PubMed ID: 7902528
[TBL] [Abstract][Full Text] [Related]
15. Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus type 1.
Yonezawa A; Hori T; Takaori-Kondo A; Morita R; Uchiyama T
J Virol; 2001 May; 75(9):4258-67. PubMed ID: 11287575
[TBL] [Abstract][Full Text] [Related]
16. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1.
Armstrong SJ; McInerney TL; McLain L; Wahren B; Hinkula J; Levi M; Dimmock NJ
J Gen Virol; 1996 Dec; 77 ( Pt 12)():2931-41. PubMed ID: 9000083
[TBL] [Abstract][Full Text] [Related]
17. Interaction of human immunodeficiency virus type 1 envelope glycoprotein V3 loop with CCR5 and CD4 at the membrane of human primary macrophages.
Rabehi L; Seddiki N; Benjouad A; Gluckman JC; Gattegno L
AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1605-15. PubMed ID: 9870313
[TBL] [Abstract][Full Text] [Related]
18. Conformational perturbation of the envelope glycoprotein gp120 of human immunodeficiency virus type 1 by soluble CD4 and the lectin succinyl Con A.
Pal R; DeVico A; Rittenhouse S; Sarngadharan MG
Virology; 1993 Jun; 194(2):833-7. PubMed ID: 8503188
[TBL] [Abstract][Full Text] [Related]
19. Evidence by peptide mapping that the region CD4(81-92) is involved in gp120/CD4 interaction leading to HIV infection and HIV-induced syncytium formation.
Kalyanaraman VS; Rausch DM; Osborne J; Padgett M; Hwang KM; Lifson JD; Eiden LE
J Immunol; 1990 Dec; 145(12):4072-8. PubMed ID: 1701782
[TBL] [Abstract][Full Text] [Related]
20. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.
Wu L; Gerard NP; Wyatt R; Choe H; Parolin C; Ruffing N; Borsetti A; Cardoso AA; Desjardin E; Newman W; Gerard C; Sodroski J
Nature; 1996 Nov; 384(6605):179-83. PubMed ID: 8906795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
